Ovelle is developing in vitro gametogenesis (IVG) technology to produce human eggs from somatic cells by inducing meiosis in human induced pluripotent stem cells (iPSCs). This approach aims to make fertility treatments more effective and affordable, addressing the emotional and financial burdens faced by couples struggling with infertility.
Funding
Funding not disclosed
Founders
Product
Problem
In vitro fertilization (IVF), a common treatment for infertility, can be costly, invasive, and is not always successful. Millions of women globally struggle with infertility, which impacts physical health and places an emotional burden on individuals and relationships.
Solution
Ovelle is developing in vitro gametogenesis (IVG) technology, which aims to produce human eggs from somatic cells by inducing meiosis in human induced pluripotent stem cells (iPSCs). This technology has the potential to be more effective, less invasive, and more affordable than current IVF treatments. Ovelle manipulates the expression of transcription factors and RNA-binding proteins to create the cell types of the ovary from human iPSCs. The company has produced meiotic oogonia-like cells from human iPSCs and plans to incorporate these cells into ovarian organoids to create synthetic ovaries capable of producing eggs.
Target Audience
The primary target audience includes couples struggling with infertility and seeking more effective and affordable fertility treatments.
Features
- Technology to create cell types of the ovary from human induced pluripotent stem cells (iPSCs)
- Manipulation of transcription factors and RNA-binding proteins
- Production of meiotic oogonia-like cells from human iPSCs
- Cyclical, iterative method that accelerates IVG research
- Computational screening using algorithms to identify key transcription factors in germ cell development
- Laboratory validation to test factors in stem cell cultures
- Data analysis to refine computational models